Y-mAbs Therapeutics, Inc. (YMAB)
Largest Insider Buys in Sector
YMAB Stock Price History Chart
YMAB Stock Performance
About Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line …
Insider Activity of Y-mAbs Therapeutics, Inc.
Over the last 12 months, insiders at Y-mAbs Therapeutics, Inc. have bought $3.53M and sold $5.99M worth of Y-mAbs Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Y-mAbs Therapeutics, Inc. have bought $1.44M and sold $27.42M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Wedell-Wedellsborg Johan (director) — $1.77M. WG Biotech ApS (director) — $1.77M.
The last purchase of 109,318 shares for transaction amount of $765,075 was made by WG Biotech ApS (director) on 2023‑12‑11.
List of Insider Buy and Sell Transactions, Y-mAbs Therapeutics, Inc.
| 2024-09-16 | Sale | CHIEF BUSINESS OFFICER | 30,000 0.0671% | $12.97 | $389,100 | +8.84% | ||
| 2024-09-13 | Sale | CHIEF BUSINESS OFFICER | 65,000 0.143% | $13.47 | $875,550 | +2.98% | ||
| 2024-08-28 | Sale | SVP & CHIEF TECHNICAL OFFICER | 50,000 0.112% | $15.37 | $768,500 | -8.71% | ||
| 2024-08-26 | Sale | SVP & CHIEF OPERATING OFFICER | 5,000 0.0109% | $14.69 | $73,450 | -7.01% | ||
| 2024-06-11 | Sale | CHIEF BUSINESS OFFICER | 35,000 0.0797% | $12.00 | $420,000 | +12.03% | ||
| 2024-06-10 | Sale | CHIEF BUSINESS OFFICER | 35,000 0.0795% | $12.03 | $421,050 | +11.02% | ||
| 2024-06-10 | Sale | director | 722 0.0016% | $12.00 | $8,664 | +11.02% | ||
| 2024-05-31 | Sale | EVP, CFO, SECRY & TREAS. | 31,371 0.0713% | $12.07 | $378,648 | +9.69% | ||
| 2024-05-30 | Sale | EVP, CFO, SECRY & TREAS. | 28,629 0.0653% | $12.03 | $344,407 | +10.12% | ||
| 2024-05-23 | Sale | CHIEF BUSINESS OFFICER | 7,351 0.0176% | $13.00 | $95,563 | +5.85% | ||
| 2024-05-21 | Sale | CHIEF BUSINESS OFFICER | 25,000 0.0544% | $12.00 | $300,000 | +4.06% | ||
| 2024-03-05 | Sale | CHIEF BUSINESS OFFICER | 3,900 0.0088% | $16.44 | $64,116 | -16.86% | ||
| 2024-03-05 | Sale | SVP & CHIEF COMMERCIAL OFFICER | 1,682 0.0038% | $16.55 | $27,837 | -16.86% | ||
| 2024-03-05 | Sale | SVP & CHIEF MEDICAL OFFICER | 1,711 0.0039% | $16.53 | $28,283 | -16.86% | ||
| 2023-12-15 | Sale | Chief Business Officer | 50,000 0.1144% | $6.61 | $330,500 | +104.05% | ||
| 2023-12-14 | Sale | Chief Business Officer | 50,000 0.113% | $6.83 | $341,500 | +98.10% | ||
| 2023-12-13 | Sale | Chief Business Officer | 50,000 0.1109% | $6.58 | $329,000 | +98.10% | ||
| 2023-12-11 | director | 109,318 0.2637% | $7.00 | $765,075 | +103.61% | |||
| 2023-12-11 | director | 109,318 0.2637% | $7.00 | $765,075 | +103.61% | |||
| 2023-12-08 | director | 18,503 0.0418% | $6.99 | $129,379 | +90.62% |
Insider Historical Profitability
| Wedell-Wedellsborg Johan | director | 4559233 10.2294% | $15.63 | 7 | 17 | <0.0001% |
| WG Biotech ApS | director | 4559233 10.2294% | $15.63 | 7 | 8 | <0.0001% |
| Rajah Vignesh | SVP & CHIEF MEDICAL OFFICER | 33889 0.076% | $15.63 | 4 | 1 | <0.0001% |
| HEALY JAMES | director | 2194278 4.9232% | $15.63 | 2 | 0 | +8.58% |
| TYAGI ASHU | director | 1392740 3.1249% | $15.63 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $46.46M | 6.51 | 2.86M | -2.05% | -$972,722.03 | <0.01 | |
| Paradigm BioCapital Advisors LP | $36.32M | 5.09 | 2.23M | New | +$36.32M | 1.32 | |
| Sofinnova | $35.68M | 5 | 2.19M | 0% | +$0 | 0.07 | |
| The Vanguard Group | $33.65M | 4.72 | 2.07M | -7.79% | -$2.84M | <0.01 | |
| Polar Capital | $29.77M | 4.17 | 1.83M | -10.98% | -$3.67M | 0.17 |